Microtubules have been among the most successful targets in anticancer therapy and a large number of microtubule-targeting agents (MTAs) are in various stages of clinical development for the treatment of several malignancies. Given that injury and diseases in the central nervous system (CNS) are accompanied by acute or chronic disruption of the structural integrity of neurons and that microtubules provide structural support for the nervous system at cellular and intracellular levels, microtubules are emerging as potential therapeutic targets for treating CNS disorders. It has been postulated that exogenous application of MTAs might prevent the breakdown or degradation of microtubules after injury or during neurodegeneration, which will thereby aid in preserving the structural integrity and function of the nervous system. Here we review recent evidence that supports this notion and also discuss potential risks of targeting microtubules as a therapy for treating nerve injury and neurodegenerative diseases.

Keywords: Microtubules; Neoplasms; Nerve Degeneration; Wounds and Injuries

Grant Support: This study of E.M.H. is supported by the Institutional Grant of the Korea Institute of Science and Technology (2V03430). This study of B.D.L is supported by the grant of NRF (NRF-2012R1A1A1010564, NRF-2012-0001161) funded by Korea Ministry of Science.

Conflict of Interest: No potential conflict of interest relevant to this article was reported.

INTRODUCTION

Microtubules are major components of the cytoskeleton in all cells. They are dynamic macromolecular structures composed of polarized tubulin dimers with fast-growing plus ends and more stable minus ends, usually organized in a radial array with plus ends directed toward the cell periphery (see Glossary Appendix). Microtubules form a mechanical framework throughout the cell and play key roles in a variety of cellular processes, such as cell proliferation, migration, and differentiation. For this reason an expanding list of microtubule-targeting agents (MTAs) has been developed for different purposes, including for use as...
antifungal agents, pesticides, and anticancer agents (see Glossary Appendix).

It is well known that in dividing cells, microtubules constituting the mitotic spindle are highly dynamic and are extremely susceptible to perturbations. Such hypersensitivity of dynamic microtubules to perturbations during cell division provides an explanation for why targeting microtubules with MTAs have proven to be highly effective in patients with cancer [1]. In addition to dividing cells, postmitotic neurons harbor microtubules that undergo dynamic assembly and disassembly, clustering and splaying, and local stabilization and destabilization. In recent years, translational neuroscientists have developed an intriguing hypothesis proposing microtubules as a promising therapeutic target for treating nervous system injury or neurodegenerative diseases [2-4]. Given that injury and disease of the nervous system are often accompanied by acute or chronic disruption of the structural integrity of neurons and that microtubules provide structural support for the nervous system at cellular and intracellular levels, it has been suggested that exogenous application of MTAs might prevent the breakdown or degradation of microtubules after injury or during neurodegeneration, which will thereby aid in preserving the structural integrity and function of the nervous system. Here we review recent proof-of-principle experiments that support this notion and also discuss potential risks of targeting microtubules as a therapy for treating nerve injury and neurodegenerative diseases.

NEURONAL MICROTUBULES

The dynamic lengthening and shortening of spindle microtubules that mediate chromosome segregation during cell division is an iconic process illustrating the dynamicity of microtubules. Microtubules in nonneuronal cells are in constant dynamic flux being taken apart and rebuilt, consistent with their need to rapidly reorganize during cell division, migration, and differentiation. Such dynamic microtubules are susceptible for perturbations, such as exposure to cold and depolymerizing drugs. By contrast, neuronal microtubules are resistant to depolymerizing conditions, which would normally cause microtubules to disassemble in nonneuronal cells [5], and the presence of such ‘stable’ microtubules have long been thought to provide a structural framework for the complex neuronal architecture. Moreover, given the highly compartmentalized nature of neurons, neuronal function heavily relies on active transport and communication between the cell body and the axon, and thus structural integrity is essential for neuronal microtubules to serve as stable tracks for transport of proteins, vesicles and organelles over long distances [6].

Contrary to conventional wisdom that neuronal microtubule network is composed of stable microtubules, the discovery of a specific class of microtubule-associated proteins, known as plus end-interacting proteins (+TIPs) has revealed that a fraction of neuronal microtubules is quite dynamic [7,8]. Recently, in vivo imaging of +TIPs that bind specifically to actively growing microtubule plus ends confirmed that neuronal microtubules exhibit dynamicity even in fully mature neurons, as in nonneuronal cells [8]. Increasing lines of evidence suggest that such dynamic nature of neuronal microtubules is essential for normal function: it is crucial not only during development to organize and construct the complex nervous system, but also in adult life to maintain the ability to undergo structural rearrangement required for synaptic plasticity. It appears that tight spatial and temporal regulation of microtubule assembly/disassembly, bundling/splaying, stability/dynamics is key to function both during development and adult life, and multiple layers of regulation exist to achieve the balance between opposing properties of microtubules. To reconcile rather conflicting needs for dynamics and stability, it has been suggested that neurons contain multiple classes of microtubule polymers that differ in stability [9,10] and that regions of stable, less stable, and labile microtubules might exist as distinct domains on individual microtubules [11]. In that way, most stable microtubule fraction unique to neurons would serve to preserve the organization, whereas the dynamic class residing in specific regions might be responsible for the structural modification in response to physiological stimuli.

Given the complex organization and intricate regulation of microtubules in neurons, it is no surprise that dysfunction of the microtubule network has been associated with a number of nervous system disorders. Disruption of the structural integrity of the microtubule network and interruption of microtubule function are observed after traumatic injury in the nervous system [8,12], as well as in a number of neurological disorders, ranging from neurodevelopmental disorders to neurodegenerative diseases [13-16]. Accordingly, stabilization of microtubules has emerged as a possible therapeutic approach for treating injuries and diseases in the central nervous system (CNS). This expectation has gathered more attention with the development of MTAs that penetrate the blood-brain-barrier (BBB), such as epothilones, and noscapine and analogues. The feasibility of such approach is currently under evaluation by applying clinically ap-
proved MTAs in animal models of CNS injury or neurodegenerative diseases, as discussed in the following sections.

**MICROTUBULES ARE POTENTIAL TARGETS FOR ENHANCING AXON REGENERATION AFTER TRAUMATIC INJURY**

Traumatic injuries to the CNS can sever axonal tracts and lead to functional deficits. The degree of functional loss varies, but CNS injuries have the potential to permanently debilitate the victims, largely because damaged axons in the CNS fail to regrow after injury. Inability to restore the compromised connections is due to both the diminished intrinsic growth state of a neuron and the hostile extracellular environment of the CNS [17,18]. Intrinsically, neurons undergo a developmental decline in the potential to grow axons, and extrinsically, severed axons encounter a milieu of growth impediments, exemplified by the presence of inhibitory molecules comprising the glial scar [17,19]. Of note, microtubule dynamics play a part in the regulation of both the intrinsic growth state and the formation of a glial scar. On the one hand, severed axons form dystrophic retraction bulbs at the ends, which are morphological hallmarks of lesioned axons that fail to regrow [12]. Disorganized microtubules have been suggested to underlie the formation of retraction bulbs and subsequent regeneration failure [12]. Indeed, reorganization of microtubules in the severed axon was sufficient to prevent the generation of retraction bulbs, and subsequently promoted axon growth over potent growth impediments [20]. On the other hand, microtubule dynamics regulate key processes of scarring, including cell proliferation, migration, as well as intracellular trafficking and secretion of extracellular matrix molecules [3]. Thus, adequate control over microtubule dynamics is likely to yield beneficial outcomes by enhancing intrinsic axon growth ability and alleviating glial inhibition.

Recent studies have presented proof-of-principle experiments supporting the notion that modulation of microtubule dynamics can enhance axon regeneration. Hellal et al. [3] delivered paclitaxel directly to the injury site in a rodent model of spinal cord injury and found that local administration of low-dose paclitaxel promoted axon regeneration. Paclitaxel treatment could reduce scar formation and induce the growth of serotonergic (5HT) axons. Importantly, these anatomical changes were accompanied by recovery of motor function [3], suggesting an exciting possibility of exploiting the growing collection of MTAs to the treatment of CNS repair. Similarly, application of paclitaxel directly around the lesion site improved axon regeneration after optic nerve crush when combined with a lens injury [21], a procedure that transforms retinal ganglion cells into a growth-competent state [22]. Local administration, but not intravitreal injection, of paclitaxel delayed scar formation, prevented macrophage infiltration into the lesion site, and enhanced axon regeneration [21], further supporting the notion that manipulation of microtubules at the injury site can yield beneficial outcomes. However, in a recent study, intrathecal infusions of paclitaxel did not promote axon regeneration nor did it improve functional recovery in a rodent model of spinal contusion injury, although administration of paclitaxel did reduce scarring [23]. These disparate results imply that a comprehensive and mechanistic understanding is needed before moving forward with translation of MTAs for repair after CNS injuries. Furthermore, it should be noted that, in the aforementioned studies [3,21] paclitaxel had to be delivered directly to the lesion site to produce desired outcome, because this drug cannot cross the BBB. Application of paclitaxel for treating CNS injury, thus, has limited therapeutic value, as local administration of a drug directly to the injury site often requires invasive procedures, which can induce further CNS damage. Therefore, it will be intriguing to examine if axon regeneration and neural repair can be promoted by administration of MTAs that penetrate the BBB.

**TARGETING MICROTUBULES AS AN APPROACH FOR TREATING NEURODEGENERATIVE DISEASES**

Neurodegenerative diseases show common pathological features, including abnormal protein aggregation, mitochondrial dysfunction, and disease-specific neuronal degeneration. Interestingly, several pathogenic proteins, such as Tau, α-synuclein, Parkin, leucine-rich repeat kinase 2 (LRRK2), and Huntingtin, related to neurodegenerative diseases have been reported to directly bind tubulin or modulate microtubule stability. Currently, increasing lines of evidence suggest that MTAs can ameliorate the pathogenic symptoms in animal models of neurodegenerative diseases. In addition to administrating drugs that directly stabilize microtubules, strategies to tackle microtubule-based transport system are also under development, as impairment in the axonal transport has recently emerged as a common factor in several neurodegenerative diseases [6,24]. It remains to be determined whether interventions that correct transport deficits can confer therapeutic effects and slow the progression of neu-
Alzheimer Disease or Tauopathies

The presence of intraneuronal neurofibrillary tangles (NFT) composed of Tau is a pathological marker found in multiple neurodegenerative diseases, including Alzheimer disease (AD), frontotemporal dementias, corticobasal degeneration, progressive supranuclear palsy, Pick disease, and parkinsonism-linked chromosome 17 [25]. Under normal physiological conditions, Tau is enriched in axons and functions to stabilize microtubules. However, under pathological conditions, such as AD, Tau progressively detaches from microtubules and becomes hyperphosphorylated [26,27]. It has been postulated that the abnormal dissociation of Tau from microtubules disrupts the dynamics and organization of axonal microtubules, which can lead to microtubule destabilization, axonal transport deficits, and neurodegeneration. Accordingly, attempts have been made to alleviate pathological defects of neurodegenerative tauopathies by administering microtubule-stabilizing MTAs. To test this possibility, paclitaxel was applied to Tau transgenic mice that develop NFT-like inclusions in the brain stem and the spinal cord [4]. Drug absorption in Tau transgenic mice at neuromuscular junctions increased microtubule density and enhanced axonal transport in spinal motor neurons, which project to striated muscles where there is no BBB [4]. Unfortunately, applying paclitaxel is limited in other animal models of tauopathies, which more closely recapitulate human pathology, due to the poor BBB penetration of paclitaxel.

Applying MTAs to treat CNS diseases has become more feasible by the development of MTAs that cross the BBB, such as epothilone D [28]. In PS19 transgenic mice — which develop forebrain accumulations of insoluble Tau inclusions, axonal degeneration, and neuronal loss — intraperitoneal injections of epothilone D significantly reduced dystrophic axons and increased microtubule density [29]. Barnes maze test of learning and memory revealed that such changes in axonal architecture were accompanied by improvement of cognitive performance in the PS19 mice [29]. These proof-of-principle experiments suggest brain-penetrant MTAs as potential treatments for AD and other neurodegenerative tauopathies.

Parkinson Disease

In general, Parkinson disease (PD) patients show defective locomotive movement caused by the reduction of dopamine contents in the striatum. Degeneration of nigrostriatal dopaminergic synaptic terminals precedes the loss of dopaminergic neurons in the substantia nigra [30]. A variety of environmental and genetic factors have been documented to cause such selective loss. Exposure to environmental factors, such as rotenone and 1-methyl-4-phenylpiridinium (MPP+), either by systemic or chronic administration induces PD-like symptoms and degeneration of dopaminergic neurons in animal models. The neuronal loss induced by these factors has been suggested to occur through inhibition of mitochondrial complex I and depolarization of microtubules [31]. The disruption of microtubule network has been shown to induce the accumulation of dopamine vesicles at the soma, which causes oxidative damage by the oxidation of leaked dopamine from the accumulated dopamine vesicles [31]. Supporting the relevance of disrupted microtubule network in rotenone-induced parkinsonism, the selective loss of dopaminergic neurons induced by rotenone could be mimicked by other microtubule-depolymerizing agents, such as colchicine or nocodazole, and the loss of dopaminergic neurons could be reversed by applying paclitaxel which stabilizes microtubules [31]. Furthermore, epothilone D has been shown to prevent defects in microtubules and attenuate the degeneration of nigrostraial track induced by MPTP, a precursor of MPP+ [32].

In addition to environmental toxins, several proteins related to PD, such as α-synuclein, Parkin, and LRRK2, have been shown to directly bind tubulin (or microtubules) and modulate microtubule stability [33-35]. Especially, overexpression of α-synuclein and pathogenic mutants of LRRK2 resulted in increasing Tau phosphorylation, and axonal transport deficits induced by LRRK2 could be reversed by applying a tubulin deacetylase inhibitor, trichostatin A [36]. Parkin, a protein E3 ligase linked to PD, is known to ubiquitinate α- and β-tubulin, leading to their degradation through activation of the proteasomal pathway [37]. The physiological significance of the interaction between microtubules and several proteins encoded by genes associated with PD are currently not fully understood, but such interactions might play a part in regulating microtubule stability and microtubule-based transport in neurons.

CHALLENGES

Lessons Learned From Cancer

Microtubules have been among the most successful targets in anticancer therapy and a large number of MTAs are in various stages of clinical development for the treatment of several malignancies [1]. As such, this class of drugs has been intensively scruf-
tinized, revealing compound-specific or rather common side-effects. The clinical success of MTAs has often been hampered by the risk of inducing peripheral neuropathy, commonly referred to as chemotherapy-induced peripheral neuropathy [38] (see Glossary Appendix). Given systematically at cancer-reducing dosages, treatment with paclitaxel and related drugs frequently produces painful neuropathies and can affect quality of life even after the completion of chemotherapy [38-40]. Peripheral sensory nerves are especially sensitive to MTA exposure, which might be associated with their long length of axons, but the hypersensitivity of sensory neurons to MTAs is not understood at a mechanistic level. There have been few reports of CNS toxicity so far with the currently prescribed MTAs, presumably because of the fact that a large number of MTAs have poor BBB permeability. However, it is possible that the more recently approved MTAs, especially those that penetrate the BBB, might be associated with, or cause CNS toxicity. Therefore, studies aiming at testing the feasibility of applying BBB-penetrating MTAs for the treatment of neurodegenerative diseases should also thoroughly examine whether such administration affects the intact nervous system, both the CNS and the PNS. In this regard, the development of reliable and predictive models of neurotoxicity should be of great use.

**Fundamental Challenges of Microtubule-based Approaches**

Aside from drug toxicity, the multiple roles of microtubules in the plethora of cellular activities raise a fundamental issue of microtubule-based approaches related to specificity. Given that microtubules are essential components in all cells, it is possible that MTAs delivered to the system with the purpose of acting on neuronal microtubules also substantially affect microtubules in other cells. To gain insights into this issue, it will be of paramount importance to understand why systematic application of anticancer agents preferentially affects sensory neurons in the PNS, how neuronal microtubules differ from those of non-neuronal cells, and how neuronal microtubules and microtubule-based transport system are regulated.

However, it is also possible that, by interfering multiple processes, microtubule-based approaches might induce the desired effect to the entire biological system, especially in the context of CNS injury and diseases where injury responses or development of diseases are quite complex. As discussed above, paclitaxel could promote neural repair by promoting axonal regrowth, decreasing scar formation, and reducing macrophage infiltra-

**CONCLUDING REMARKS AND FUTURE PERSPECTIVES**

MTAs have been widely prescribed as components of chemotherapy. In addition to treating malignancy, translational neuroscientists are pointing to MTAs as promising therapeutic agents for treating injury and disease in the CNS. In this respect, MTAs that cross the BBB are gathering particular attention. However, a comprehensive evaluation of the different classes of MTAs in the context of neurological disorders and diseases has not yet been achieved. Given the well-known peripheral neuropathy induced by chemotherapy, a critical challenge facing the development of CNS-directed microtubule-stabilizing therapies is finding ways to specifically retain MTAs in the CNS to allow for prolonged drug activity where needed, while minimizing sustained peripheral exposure.

It is obvious that advances in understanding the function and regulatory mechanism of neuronal microtubules has high clinical and public health significance and will lead to improved targeting and development of therapeutic interventions. The risks and benefits of targeting microtubules should be thoroughly considered to aid in planning future investigations. We hope that as we gain more knowledge and insight into the molecular mechanisms of action of MTAs and regulatory mechanisms of neuronal microtubules, we will be able to design better ways to target microtubules and produce desired clinical activities.

**ACKNOWLEDGEMENTS**

We apologize to authors whose work could not be cited or cited only through review articles due to space constraints.

**REFERENCES**

1. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803.
2. Brunden KR, Ballatore C, Lee VM, Smith AB 3rd, Trojanowski JQ.
Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 2012;40:661-6.

3. Hellal F, Hurtado A, Ruschel J, Flynn KC, Laskowski CJ, Umlauf M, et al. Microtubule stabilization reduces scarring and causes axon regeneration after spinal cord injury. Science 2011;331:928-31.

4. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 2005;102:227-31.

5. Sahenk Z, Brady ST. Axonal tubulin and microtubules: morphologic evidence for stable regions on axonal microtubules. Cell Motil Cytoskeleton 1987;8:155-64.

6. Maday S, Twelvetrees AE, Moughamian AJ, Holzbaur EL. Axonal transport: cargo-specific mechanisms of motility and regulation. Neuron 2014;84:292-309.

7. Hur EM, Sajjilafu, Lee BD, Kim SJ, Xu WL, Zhou FQ. GSK3 controls axon growth via CLASP-mediated regulation of growth cone microtubules. Genes Dev 2011;25:1968-81.

8. Kleede T, Marinkovic P, Williams PR, Stern S, Weigand EE, Engerer P, et al. An assay to image neuronal microtubule dynamics in mice. Nat Commun 2014;5:4827.

9. Brady ST, Tytell MJ, Lasek RJ. Axonal tubulin and axonal microtubules: biochemical evidence for cold stability. J Cell Biol 1984;99:1716-24.

10. Song Y, Kirkpatrick LL, Schilling AB, Helseth DL, Chabot N, Keilor JW, et al. Transglutaminase and polyamination of tubulin: posttranslational modification for stabilizing axonal microtubules. Neuron 2013;78:109-23.

11. Baas PW. Microtubule stability in the axon: new answers to an old mystery. Neuro 2013;78:3-5.

12. Ertürk A, Hellal F, Enes J, Bradke F. Disorganized microtubules underlie the formation of retraction bulbs and the failure of axonal regeneration. J Neurosci 2007;27:9169-80.

13. Duncan JE, Goldstein LS. The genetics of axonal transport and axonal transport disorders. PLoS Genet 2006;2:e124.

14. Cederquist GY, Luchniak A, Tischfield MA, Peeva M, Song Y, Menezes MP, et al. An inherited TUBB3 mutation alters a kinesin-binding site and causes polymicrogyria, CFEOM and axon dysinnervation. Hum Mol Genet 2012;21:5484-99.

15. Tischfield MA, Baris HN, Wu C, Rudolph G, Van Maldergem L, He W, et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell 2010;140:74-87.

16. Fanara P, Banerjee J, Hueck RV, Harper MR, Awada M, Turner H, et al. Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis. J Biol Chem 2007;282:23465-72.

17. Sun F, He Z. Neuronal intrinsic barriers for axon regeneration in the adult CNS. Curr Opin Neurobiol 2010;20:510-8.

18. Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 2006;7:617-27.

19. Gregg JM, DePaul MA, Filous AR, Lang BT, Tran A, Silver J. Functional regeneration beyond the glial scar. Exp Neurol 2014;253:197-207.

20. Hur EM, Yang IH, Kim DH, Byun J, Sajjilafu, Xu WL, et al. Engineering neuronal growth cones to promote axon regeneration over inhibitory molecules. Proc Natl Acad Sci U S A 2011;108:5057-62.

21. Sengottuvel V, Leibinger M, Preimer M, Andreakaki A, Fischer D. Taxol facilitates axon regeneration in the mature CNS. J Neurosci 2011;31:2688-99.

22. Leon S, Yin Y, Nguyen J, Irwin N, Benowitz LJ. Lens injury stimulates axon regeneration in the mature rat optic nerve. J Neurosci 2000;20:4615-26.

23. Popovich PG, Tovar CA, Lemoshow S, Yin Q, Jakeman LB. Independent evaluation of the anatomical and behavioral effects of Taxol in rat models of spinal cord injury. Exp Neurol 2014;261:97-108.

24. Millecamps S, Julien JP. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 2013;14:161-76.

25. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001;24:1121-59.

26. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993;11:153-63.

27. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95-130.

28. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 2010;30:13861-6.

29. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003;39:889-909.

30. Andrieux A, Salin P, Schweitzer A, Begou M, Pachoud B, Brun P, et al. Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol Psychiatry 2006;60:1224-30.

31. Cartelli D, Casagrande F, Busceti CL, Bucc D, Molinaro G, Trafi
cante A, et al. Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective. Sci Rep 2013;3:1837.
33. Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, et al. Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J Alzheimers Dis 2004;6:435-42.
34. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability: a point of convergence in parkinsonian neurodegeneration? J Neurochem 2009;110:1514-22.
35. Yang F, Jiang Q, Zhao J, Ren Y, Sutton MD, Feng J. Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem 2005;280:17154-62.
36. Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM, et al. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun 2014;5:5245.
37. Ren Y, Zhao J, Feng J. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 2003;23:3316-24.
38. Kudlowitz D, Muggia F. Defining risks of taxane neuropathy: insights from randomized clinical trials. Clin Cancer Res 2013;19:4570-7.
39. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:1941-67.
40. Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer 2011;11:73-81.
Appendix 1. GLOSSARY

Microtubule Plus and Minus Ends
Microtubules are composed of dimers of α- and β-tubulin that assemble head-to-tail, forming a polar protofilament. Based on the analysis of microtubules assembled in vitro, the faster polymerizing end was termed the plus end and the more slowly polymerizing end the minus end. In cells, minus end of the microtubule filament is often anchored, whereas the plus end is directed towards cell periphery and is dynamic, alternating between phases of growth and shrinkage.

Microtubule-Targeting Agents
Microtubule-Targeting Agents (MTAs) comprise a large number of chemically diverse chemicals that bind to distinct sites of microtubules (or soluble tubulin) and interfere with the normal functions of microtubules. MTAs are potent mitotic poisons that are often classified into two groups, microtubule stabilizers (e.g., taxanes, epothilones, etc.) and destabilizers (e.g., vinca alkaloids, colchicine, nocodazole, cryptophycins, etc.), according to their effects on microtubule polymerization and polymer mass at high concentrations. However, at low concentrations, both classes of compounds potently suppress microtubule dynamics, with little or no effects on polymer mass.

Chemotherapy-Induced Peripheral Neuropathy
A chief limitation in the use of chemotherapeutic agents is the high rate of neurological toxicity often caused by damage to peripheral nerves. Chemotherapy-induced peripheral neuropathy is more frequent in patients with pre-existing neuropathy and may also significantly diminish the quality of life of patients even after the completion of chemotherapy. Commonly prescribed chemotherapy drugs that frequently cause severe symptoms include MTAs, such as taxanes and vinca alkaloids. The underlying mechanism for the preferential toxicity of MTAs for the nervous system is not understood and there is currently no effective treatment.

1) Carvalho P, Tirnauer JS, Pellman D. Surfing on microtubule ends. Trends Cell Biol 2003;13:229-37.
2) Howard J, Hyman AA. Dynamics and mechanics of the microtubule plus end. Nature 2003;422:753-8.
3) Akhmanova A, Steinmetz MO. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Nat Rev Mol Cell Biol 2008;9:309-22.
4) Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:1941-67.